July 29, 2016
A D.C. federal judge on Thursday rejected Otsuka Pharmaceutical's effort to derail a rival version of schizophrenia drug Abilify Maintena, calling its logic "convoluted" and obviously aimed at perpetually thwarting competition.
January 07, 2016
A D.C. federal judge on Thursday was harshly skeptical of Otsuka's bid to reverse the U.S. Food and Drug Administration's approval of a rival version of its schizophrenia drug Abilify Maintena, openly doubting that Otsuka's exclusivity was as broad as it claimed.
October 20, 2015
Otsuka Pharmaceutical Co. Ltd. is suing in D.C. federal court over the U.S. Food and Drug Administration's approval of a rival version of its schizophrenia drug Abilify Maintena, alleging that "regulatory sleight of hand" improperly nullified its exclusivity.